Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation. by Skeoch, S et al.
1Scientific RepoRts | 7: 827  | DOI:10.1038/s41598-017-00989-w
www.nature.com/scientificreports
Imaging atherosclerosis in 
rheumatoid arthritis: evidence 
for increased prevalence, altered 
phenotype and a link between 
systemic and localised plaque 
inflammation
S. Skeoch  1,2, P. L. Hubbard Cristinacce3,4, H. Williams5, P. Pemberton6, D. Xu7, J. Sun7, J. 
James5, C. Yuan7, T. Hatsukami7, P. D. Hockings8,9, M. Y. Alexander10, J. C. Waterton  3 & I. N. 
Bruce1,2
In rheumatoid arthritis (RA), chronic inflammation is thought to drive increased cardiovascular risk 
through accelerated atherosclerosis. It may also lead to a more high-risk plaque phenotype. We sought 
to investigate carotid plaque phenotype in RA patients using Dynamic Contrast-Enhanced MRI (DCE-
MRI) and Fludeoxyglucose Positron Emission Tomography(FDG-PET). In this pilot study, RA patients 
and age/sex-matched controls were evaluated for cardiovascular risk factors and carotid plaque on 
ultrasound. Subjects with plaque >2 mm thick underwent DCE-MRI, and a subgroup of patients had 
FDG-PET. Comparison of MRI findings between groups and correlation between clinical, serological 
markers and imaging findings was undertaken. 130 patients and 62 controls were recruited. Plaque was 
more prevalent in the RA group (53.1% vs 37.0%, p = 0.038) and was independently associated with 
IL6 levels (HR[95%CI]: 2.03 [1.26, 3.26] per quartile). DCE-MRI data were available in 15 patients and 5 
controls. Higher prevalence of plaque calcification was noted in RA, despite similar plaque size (73.3% 
vs 20%, p = 0.04). FDG-PET detected plaque inflammation in 12/13 patients scanned and degree of 
inflammation correlated with hs-CRP (r = 0.58, p = 0.04). This study confirms increased prevalence of 
atherosclerosis in RA and provides data to support the hypothesis that patients have a high-risk plaque 
phenotype.
Rheumatoid arthritis (RA) is a chronic autoimmune disease which affects 1% of the adult population1. It is char-
acterised by synovial joint inflammation which causes progressive disabling arthritis. Patients also suffer with 
extra-articular disease and a high systemic inflammatory burden. RA is associated with premature death, the 
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leading cause being cardiovascular disease (CVD)2. Studies have demonstrated that the excess burden of CVD 
in RA is equivalent to that seen in type two diabetes3. Evidence suggests a more aggressive clinical phenotype of 
CVD in RA, with patients having fewer warning symptoms prior to major events, and higher case-fatality rates4, 5.
Although an increased prevalence of some traditional risk factors is seen in RA, they do not fully explain 
the excessive risk. Chronic inflammation is thought to be a major driver of CVD in this population6. Although 
mechanisms are unclear, inflammation may not only influence traditional cardiovascular risk factors such as dys-
lipidaemia, but also have direct detrimental effects on the vessel wall7, 8. Recent therapeutic advances in RA have 
led to significant improvements in outcomes of joint disease. However, the mortality gap between those with and 
without RA persists, and excess cardiovascular risk is still evident9, 10. A better understanding of the underlying 
pathological processes driving increased risk, and the potential effects of RA treatment on vascular pathology, 
would improve our ability to target cardiovascular risk reduction more effectively in this population.
Atherosclerosis, the pathological mechanism underlying most CVD in RA, is also a chronic inflammatory 
condition with immune cells playing a key role in all stages of plaque development11. In addition, plaque rupture 
(the main trigger for clinical events) is influenced by plaque composition and presence of inflammation rather 
than simply by plaque size12, 13. High risk plaque features include the presence of calcification, lipid rich necrotic 
core (LRNC), neovascularisation and inflammatory cell infiltration. In the general population there is evidence 
linking pro-inflammatory cytokines with plaque progression and destabilisation14. IL6 and TNF levels have been 
shown to be independent predictors of future cardiovascular mortality in large meta-analyses15, 16. In RA, an 
increased prevalence and faster progression of atherosclerosis is associated with inflammation17, 18 and there is 
emerging evidence that RA patients may have a more rupture-prone plaque phenotype19. In a post mortem study, 
Aubrey et al. demonstrated less stenosed, more inflammatory coronary plaques in RA patients who had died from 
acute myocardial infarction (MI)19. Furthermore, Karpouzas et al., found that RA patients had a higher preva-
lence of high risk plaques on coronary CT20. The clinical phenotype of CVD with more sudden severe events may 
partly be explained by the hypothesis that patients have a more rupture prone phenotype5, 21.
Recent advances in non-invasive carotid artery imaging allow more detailed characterisation of plaque pheno-
type. Carotid plaque rupture is an important cause of stroke, however presence and composition of carotid plaque 
are also predictors of coronary disease22. Carotid magnetic resonance imaging (MRI) can be used to measure 
plaque burden and compositional features including LRNC, calcification and fibrous cap integrity23. A strong 
correlation has been established between MRI and histological findings, and MRI has been used in clinical studies 
to evaluate predictors of stroke, and response to statin therapy24, 25. More recently, carotid artery dynamic con-
trast enhanced MRI (DCE-MRI) has been developed to measure plaque neovascularisation and inflammation 
in stroke patients26. Serial images are taken before, during and after contrast injection, then contrast kinetics 
are modelled to estimate the transfer constant (Ktrans) of contrast and the fractional volume of plasma within the 
plaque (vP). Both Ktrans and vP have been shown to correlate with microvessel density, while Ktrans also correlated 
with macrophage infiltration of the plaque on histology27.
18F-fludeoxyglucose positron emission tomography (FDG-PET) is a nuclear imaging technique which can also 
be used to quantify carotid plaque inflammation. FDG is taken up preferentially in metabolically active tissues 
and when combined with MRI or CT, activity can be mapped to an anatomical location. In stroke patients, FDG is 
taken up preferentially in ‘culprit’ lesions and uptake associates strongly with macrophage density on histology28.
Maki-Petaja demonstrated an improvement in aortic inflammation on FDG-PET-CT in RA patients treated 
with anti-TNF therapy8. Haavisto et al. also recently demonstrated that carotid artery inflammation improved 
following treatment with anti-inflammatory therapy29. Although FDG-PET has been used to characterise vascu-
lar inflammation in RA, neither MRI nor PET have been utilised to investigate atherosclerotic plaque phenotype 
in RA. However the combination of imaging techniques could provide a comprehensive method with which to 
interrogate the relationship between chronic inflammation and atherosclerosis in RA, thus allowing a more strat-
ified approach to CVD risk management.
The aim of the current study was test the hypothesis that RA patients have a high-risk carotid plaque phe-
notype which can be characterised non-invasively using DCE-MRI and PET-CT. We also aimed to evaluate the 
association between clinical and serological markers of RA disease activity and plaque presence and characteris-
tics. Finally we aimed to test the feasibility of utilising DCE-MRI and FDG-PET to study carotid atherosclerosis 
in an RA population.
Patients and Methods
Study population. A cross-sectional pilot study of patients with established active RA (defined as a disease 
activity 28 score (DAS28) >3.2, diagnosed for more than 1 year) who fulfilled the 1987 ACR Criteria for RA30, 
together with age and sex matched controls, was undertaken. Patients were recruited from outpatient clinics in 
the North West of England between September 2012 and October 2014. Controls were recruited through the 
“best friend” method, whereby participants invite a friend to consider participation. Additionally, controls were 
recruited via advertisements within The University of Manchester and mailshots through The Greater Manchester 
Primary Care Research Network. Participants aged between 18 and 70 were included. Major exclusion crite-
ria included recent statin use (within 2 months of inclusion), significant renal impairment (estimated glomer-
ular filtration rate <50 ml/min/1.73 m2), any contra-indication to MRI, and a history of vasculitis. The study 
was approved by the NHS Health Research Authority (North West Research Ethics Committee, reference: 12/
NW/0117). All participants provided written informed consent and all methods were performed in accordance 
with the ethically approved protocol.
Data collection. Clinical and laboratory assessments. Participants underwent assessment of traditional 
cardiovascular risk factors and, in patients, RA disease characteristics were assessed. This included assessment of 
joint disease activity using the DAS28 score: a composite measure of tender and swollen joints, patient reported 
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disease activity and serological measure of inflammation which has been widely validated and is used in routine 
clinical practice. Disability was also evaluated using The Stanford Health Assessment Questionnaire (HAQ) in 
addition to history of extra-articular disease and treatment history. Fasting bloods were drawn for lipids, glucose, 
renal function, ESR measurement. High-sensitivity C-reactive protein (hs-CRP) was measured by an in-house 
ELISA method using anti-human CRP antibodies, calibrators and controls from Abcam (Cambridge, UK). Serum 
IL6, ICAM, VCAM1, E-selectin and P-selectin levels were all measured by ELISA using DuoSet development kits 
from R&D Systems (Abingdon, UK).
Carotid artery ultrasound. An ultrasound (US) was performed to screen for carotid plaque in the carotid bulb, 
common carotid artery and internal carotid artery within 2 cm above and below the bifurcation by one of three 
trained sonographers. All scans were performed on a Philips iU22 machine using a 9–3 MHz probe and stand-
ardised vascular protocol settings. Both arteries were scanned in transverse and longitudinal planes with the 
participants in a supine position. Plaque was defined in accordance with published recommendations (2 out of 3: 
Intimal medial thickening >1.5 mm, increased echogenicity, luminal protrusion31). For carotid plaque assessment 
on MRI, a minimum plaque thickness of >2 mm is required. Therefore only participants with plaques >2 mm 
thick were invited for MRI.
MRI assessment. Suitable participants attended for MRI within 2 weeks of initial assessment. Scans were per-
formed on a 3T Philips Achieva MRI scanner (Philips Healthcare, The Netherlands) with a specially designed 
8-channel carotid artery coil (SHCG, China). A number of sequences were acquired including T1-weighted, 
T2-weighted, proton density, magnetisation prepared rapid acquisition gradient echo (MP-RAGE) and time of 
flight angiography sequences (protocol details in supplemental data).
A DCE sequence was then performed. Briefly, 4 slices were positioned around the plaque and 20 frames were 
acquired (TR:126 ms, TE:4.61 ms, flip angle 50°, slice thickness 3 mm, matrix 260 × 260). 2 frames were acquired 
prior to injection of gadopentate dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals), concentration 
0.05 mmol/kg, injection rate: 1cc/sec then 18 frames acquired during and after injection (17.5 s/frame).
Scans were anonymised and transferred to the Vascular Imaging Laboratory, University of Washington then 
analysed with CASCADE software using previously published methods (CASCADE, Seattle, WA)32, 33. Scans 
were analysed by 2 blinded readers. Plaque dimensions were measured and a normalised wall index (a measure 
of plaque burden) was calculated by dividing the measured wall area by the sum of the wall and luminal area 
in each slice. Then compositional features were measured including presence and size of LRNC, calcification, 
intra-plaque haemorrhage and fibrous cap integrity. Contrast kinetics within the plaque were evaluated using a 
2-compartmental Patlak model from which Ktrans and vP were estimated.
FDG-PET sub-study. Consecutive RA patients undergoing MRI who had no history of cancer, uncontrolled 
diabetes or infection were invited to have a carotid FDG-PET-CT scan. Scans were performed on a Siemens 
Biograph mCT·64·S (Siemens Healthcare, Germany). Patients fasted for 6 hours prior to intravenous injection of 
200MBq 18F-FDG. Following a 2 hour resting/uptake period the PET-CT scan was performed, localised around 
the carotid bifurcation of the index artery (detailed methods in supplemental data).
PET-CT images were reconstructed using Siemens UHD (see supplemental data) then co-registered with MRI 
T1-weighted images. Volumes of interest (VOIs) were drawn around the affected artery on MRI, then plaque FDG 
uptake measured as the maximum standardised uptake values (SUVmax). A second VOI was used to derive SUVmax 
from non-atheromatous wall. An example of VOIs on PET-MRI can be seen in Fig. 1. The physicist undertaking 
the analysis was blinded to clinical, serological and MRI measurements.
Statistical analysis. This was a pilot study therefore no formal sample size was undertaken. Data were 
non-normally distributed thus cohort characteristics were summarized using median and interquartile 
range(IQR). Descriptive statistics were undertaken to compare clinical, serological and imaging findings in 
patient and control groups using non-parametric statistics. Associations of CV risk factors and RA related factors 
with presence of plaque were evaluated. Discrete variables were split into quartiles for further analysis. Hs-CRP 
and IL6 levels were undetectable in some subjects, therefore results were split into quartiles for analysis of asso-
ciation with plaque presence. Univariable logistic regression was used to evaluate associations of plaque with 
traditional and RA related risk factors. The relationship of RA related factors with plaque was interrogated with 
logistic regression models with age adjustment and then with adjustment for traditional risk factors. Finally a 
backwards stepwise multivariable regression was used to identify factors independently associated with plaque 
in RA patients. Association of disease activity and risk markers with localised plaque inflammation measured on 
MRI and PET were evaluated using the Spearman rank test.
Results
130 patients and 62 controls were recruited. Figure 2 demonstrates the flow of participants through the study. 
Baseline characteristics are summarised in Table 1. There were no significant differences in age or gender between 
the groups. However there was a higher prevalence of hypertension in the patient group (17.7% vs 3.9%, p = 0.01), 
and a higher systolic blood pressure was also noted compared with controls (136 vs 127 mmHg, p = 0.009). 
Patients also had lower total cholesterol levels and lower high density lipoprotein cholesterol (p = 0.013 and 
p = 0.045, respectively). There was an increased prevalence of carotid plaque in patients compared to controls 
(53.1% vs 37.0%, p = 0.038). When logistic regression was used to adjust for traditional cardiovascular risk factors 
and history of clinical CVD, the association between RA diagnosis and presence of plaque remained significant 
(odds ratio [95%CI]: 2.50 [1.08, 5.79]). Factors associated with presence of carotid plaque in patients are summa-
rised in Table 2.
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Figure 1. Identification of VOIs on PET-MRI. ROIs were drawn around the borders of plaque on each slice 
where plaque was seen (an example is seen in the axial image (A), yellow arrow points to VOI border). An 
equivalent number of ROIs are drawn around vessel wall on slices where no plaques are seen (an example is 
seen in (B)). An example of the ROIs on a sagittal section can be seen in (C) where each arrow points to the two 
defined ROIs, the superior one includes the atheromatous wall while the inferior ROI is of non-atheromatous 
wall.
Figure 2. Schematic flow of data collection in patients and controls recruited into the study.
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On univariable analysis age and smoking status were the only traditional risk factors associated with plaque. 
However there were also significant associations with RA related factors: DAS28 score, disability, ESR, IL6 and 
hs-CRP levels (as shown in Table 2). On adjustment for traditional risk factors, the association of plaque with 
DAS28 score and IL6 remained significant (detailed in Table 2). On multivariable analysis IL6 levels, age and 
smoking remained in the model (OR [95%CI]: 2.03 [1.26, 3.26], 1.10 [1.04, 1.18] and 8.523 [0.872, 88.13], respec-
tively). While IL6 and hs-CRP were significantly correlated (spearman rho = 0.38, p < 0.001), re-testing of the 
stepwise regression without hs-CRP did not lead to any change in the point estimate for IL6. Additionally removal 
of IL6 from the regression did not lead to inclusion of hs-CRP in the final model, suggesting that co-linearity was 
not a major issue in the analysis.
Circulating markers of endothelial activation: ICAM and e-selectin were increased in patients compared with 
controls (p = 0.04, p < 0.001, respectively) and were associated with presence of plaque on univariable analysis 
(OR [95%]: 1.007 [1.002, 1.012], 1.020 [1.0, 1.041], respectively). While VCAM-1 levels were not significantly 
higher in patients, they were associated with presence of plaque (OR [CI95%]: 1.004 [1.001, 1.007]).
Variable Patients (n = 130) Controls (n = 62) p-value
Traditional risk factors
  Sex (f) 99 (76.15) 48 (82.76) 0.311
  Age (years) 55.44 (48.83, 61.87) 56.53 (50.38, 59.33) 0.957
  Prior CVE 2 (1.54) 1 (1.67) 0.878
  Smoker 18 (13.85) 4 (6.45) 0.133
  TC:HDL 3.22 (2.68, 4.13) 3.28 (2.69, 3.87) 0.515
  TC (mmol/l) 5.1 (4.6, 5.8) 5.5 (5.0, 6.1) 0.013
  LDL (mmol/l) 2.96 (2.52, 3.6) 3.27 (2.68, 3.82) 0.068
  HDL (mmol/l) 1.6 (2.82, 1.96) 1.71 (1.42, 2.06) 0.047
  Diabetes 2 (1.54) 1 (1.67) 0.861
  Fasting glucose (mmol/l) 4.9 (4.6, 5.3) 5.2 (4.8, 5.5) 0.016
  Hypertension 23 (17.69) 2 (3.85) 0.0142
  Systolic BP (mmHg) 136 (124, 148) 127 (117, 142) 0.009
  Diastolic BP (mmHg) 81 (76, 89) 78.5 (74, 86) 0.213
  Family history of CVE 43 (33.08) 17 (28.33) 0.497
Non classical risk markers
  hs-CRP (mg/l) 2.89 (1.01, 6.18) 0.79 (0.35, 2.05) <0.001
  TNF (pg/ml) 1 (1, 45.3) 1 (1, 1) 0.125
  IL-6 (pg/ml) 1.99 (0.25, 4.69) 0.52 (0.25, 1.46) <0.001
  I-CAM (ng/ml) 146.7 [117.5, 186.1] 121.7 [106.9, 154.1] 0.004
  V-CAM1 (ng/ml) 368.5 (314.6, 449.2) 375.2 (327.7, 435.45) 0.748
  E-selectin (ng/ml) 7.24 (4.18, 15.89) 4.51 (1.37, 6.50) 0.001
  P-selectin (ng/ml) 32.41 (25.71, 39.92) 29.69 (24.27, 36.29) 0.140
  Carotid plaque 69 (53.08) 23 (37.01) 0.038
RA disease characteristics
  Disease duration 10.2 (5.3, 20.9) — —
  DAS-28 score 4.62 (3.76, 5.47) — —
  HAQ score 1.36 (0.50, 2.13) — —
  RF positive 97 (74.62) — —
  ACPA positive 107 (82.31) — —
  Seropositive (ACPA+/
or RF) 114 (87.69) — —
  Extra-articular disease 35 (26.9) — —
  Current methotrexate 
use 80 (61.5) — —
  Any DMARD therapy 
(including biologics) 115 (88.5) — —
  Current biologic therapy 38 (29.2) — —
  Current oral 
glucocorticoids 15 (11.5) — —
Table 1. Cohort Characteristics. Median (IQR) or Frequency (%) where variables are categorical. CVE: 
cardiovascular event, TC: total cholesterol, LDL: low density lipoprotein, HDL: high density lipoprotein, ACPA: 
anti citrullinated peptide antibody, RF: rheumatoid factor, DAS28: disease activity 28 score, HAQ: health 
assessment questionnaire, hs-CRP: high sensitivity C-reactive protein, IL-6: interleukin 6, I-CAM: intercellular 
adhesion molecule, VCAM-1: vascular cellular adhesion molecule 1.
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Plaque phenotype and inflammation on MRI. As shown in Fig. 2, of the plaques identified on US, 35/69 
in patients and 8/20 in controls did not meet suitability criteria for MR scanning. Additionally, although the scans 
were generally well tolerated by subjects, a number of MR scans were aborted in both groups (n = 4) and 16/36 
scans were not suitable for analysis. In most cases despite satisfactory imaging quality plaques were not large 
enough for DCE analysis. Analysis was completed in 15 patients and 5 controls (DCE analysis was not possible in 
one control due to slice positioning). A representative MR image of plaque is shown in Fig. 3.
The RA group undergoing MRI were older than the whole RA cohort (59.6[56.2, 64.5] vs 54.2[48.0, 60.9] 
years, p = 0.004) and had higher median ESR (29.5[17, 46] mm/hr vs 13[7, 27] mm/hr, p = 0.002). There were no 
significant differences in any other traditional cardiovascular risk factors or disease related factors among the RA 
group with MRI data and the whole RA cohort.
The prevalence of traditional risk factors in the patients and controls in whom MRI data were analysed, is 
described in Table 3. There was no difference in age (median [IQR]: 59.6[56.2, 64.9] and 59.0[52.5, 65.5] years, 
p = 0.57). Two patients but no controls were smokers. There was a trend towards higher LDL levels in the con-
trol group (median [IQR]: 2.96[2.13, 2.28] and 3.87[3.28, 4.33] mmol/l in patients and controls respectively, 
p = 0.081) and higher systolic blood pressure in the patient group (median [IQR]: 147[129, 161] vs 127[117, 
140] mmHg in patients and controls respectively, p = 0.079). One subject in the RA group had a history of stable 
angina. No control subjects had a history of clinical CVD.
There was no significant difference in plaque size between the groups (seen in Table 3). However, there was a 
significantly higher prevalence of calcification in patients compared to controls (73.3% vs 20%, p = 0.038). There 
were no significant differences in any other compositional features. While a degree of contrast enhancement was 
demonstrated in all patients, there was no significant difference in DCE parameters between the two groups. 
There was a trend towards an inverse association between calcium content of plaque and Ktrans measurement in 
patients (r-0.448, p = 0.093). There was no significant association between Ktrans measurements in plaque and 
hs-CRP levels (r = 0.002, p = 0.99), IL6 levels (r = 0.26, p = 0.36) or DAS28 score (r = −0.125, p = 0.61).
Plaque inflammation on 18FFDG-PET-MRI. 13 RA patients underwent carotid artery PET-CT. In all 
cases, registration was possible with MRI T1- weighted images and representative example images are presented in 
Fig. 4. FDG uptake was detected in all 13 cases and 12 out of 13 cases had an SUVmax > 1.85 (the proposed thresh-
old for carotid wall inflammation34). The median (IQR) SUVmax of plaque was 2.18 (2.00, 2.65) and SUVmax corre-
lated significantly with hs-CRP (r = 0.58, p = 0.04). There was no association with plaque volume, Ktrans, IL6 levels 
or DAS28 score (r = 0.20[p = 0.609]; r = 0.14[p = 0.74]; r = 0.13[p = 0.697]; r = −0.15[p = 0.617], respectively).
Median (IQR) SUVmax in non-atheromatous artery was 2.23(1.62, 2.56). There was a trend towards a correla-
tion between SUVmax in atheromatous and non-atheromatous wall (r = 0.42, p = 0.078). 5/13 subjects had more 
than 30% higher SUVmax values in plaque than in non-atheromatous wall, suggesting preferential plaque inflam-
mation in these cases.
Predictor
Unadjusted OR 
(CI 95%)
OR(CI95%) with 
age adjustment
OR (95%CI) with adjustment 
for traditional Risk factorsΔ
OR (95%CI) in fully 
adjusted model†
Age (years) 1.10 (1.04, 1.15) — — 1.10 (1.04, 1.18)
Gender (Male) 0.93 (0.41, 2.07) 0.89 (0.36, 2.18) — —
Current smoker 2.60 (0.87, 7.77) 4.34 (1.30, 14.45) — 8.523 (0.872, 88.13)
Hypertension 1.47 (0.58, 3.69) 1.02 (0.38, 2.73) — —
TC:HDL 1.11 (0.85, 1.44) 1.15 (0.86, 1.55) — —
Glucose 1.06 (0.79, 1.44) 1.07 (0.80, 1.44) —
Disease duration (years) 1.02 (0.99, 1.06) 1.02 (0.97, 1.05) — —
DAS28 1.66 (1.18, 2.31) 1.38 (1.02, 1.89) 1.5 (1.059, 2.35) —
HAQ* 1.63 (1.11, 2.41) 1.50 (1.00, 2.25) 1.45 (0.90, 2.35) —
Extra-articular disease 0.92 (0.45, 1.90) 0.81 (0.371, 1.75) 0.72 (0.27, 1.89) —
Seropositivity 1.17 (0.41, 3.34) 1.17 (0.55, 5.3) 0.80 (0.213, 3.06) —
Current biologic therapy 1.06 (0.49, 2.27) 1.52 (0.649, 2.268) 1.41 (0.554, 2.58) —
Traditional DMARD therapy 0.792 (0.341, 1.84) 0.690 (0.32, 1.48) 0.792 (0.341, 1.84) —
Current oral glucocorticoid therapy 0.993 (0.337, 2.92) 0.991 (0.310, 3.17) 0.884 (0.249, 3.13) —
hsCRP * 1.52 (1.10, 2.12) 1.41 (1.00, 1.99) 1.40 (0.96, 2.06) —
IL-6 * 1.45 (1.06, 1.98) 1.40 (1.01, 1.96) 1.55 (1.07, 2.25) 2.03 (1.26, 3.26)
VCAM-1 1.004 (1.001, 1.007) 1.003 (1.00, 1.007) 1.002 (0.99, 1.006) —
ICAM 1.007 (1.002, 1.012) 1.007 (1.001, 1.01) 1.004 (0.997, 1.010) —
E-selectin 1.020 (1.0, 1.041) 1.022 (0.998, 1.045) 1.01 (0.99, 1.03) —
P-selectin 0.996 (0.970, 1.02) 0.987 (0.959, 1.01) 0.99 (0.96, 1.03) —
Table 2. Factors associated with presence of carotid plaque in patients. Quartiles where*. ΔAdjusted for age, 
gender, hypertension, smoking, TC:HDL, glucose. †Stepwise logistic regression with significance level set at 
<0.1. Variables included in model: age, gender, hypertension, smoking, TC:HDL, DAS28, HAQ, hs-CRP, IL-6, 
biologic therapy traditional DMARd therapy and current oral glucocorticoid therapy. Traditional DMARD 
therapy includes: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, gold.
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Discussion
This study adds to the literature demonstrating higher prevalence of atherosclerosis in RA and an association 
between plaque and both traditional risk factors and inflammation. The association of hs-CRP with plaque pres-
ence and inflammation and the independent association of IL6 with plaque accords with the theory of the IL6/
CRP axis being a significant driver of cardiovascular risk in the general population and the hypothesis that exces-
sive inflammation contributes to increased risk in RA15.
MRI findings. Despite there being no significant difference in plaque size, an increased prevalence of carotid 
plaque calcification was noted in patients. Previous published data suggests that 14 subjects are required per 
group to compare plaque composition on MRI35. Although the control group was small, the presence of calcifica-
tion in the RA group (n = 15) was also higher than described in studies of asymptomatic individuals in the liter-
ature. Underhill et al. evaluated carotid plaque composition in 191 patients with asymptomatic carotid stenosis, 
comparing findings in those with and without significant coronary artery disease. The mean age of participants 
included in this study ranged from 57.8 and 60.5 years (in male without coronary disease and female with coro-
nary disease respectively), similar to the age of patients in the current study. Underhill et al. demonstrated a prev-
alence of calcification of 40.2% and 16% in patients with and without coronary disease respectively36. We found 
plaque calcification in 70% of patients with RA, only one of whom had a history of stable angina. Carotid plaque 
calcification is a predictor of subsequent stroke and more severe coronary disease37, 38. Although calcification is 
a sign of advanced plaque, calcium deposition can occur early, often in response to tissue necrosis or cholesterol 
deposition. Pro-inflammatory cytokines, in particular TNF, are known to upregulate signalling pathways promot-
ing vascular calcification, and higher levels of pro-inflammatory cytokines have been found preferentially in areas 
Figure 3. Representative images acquired during MRI. The small yellow arrows correspond to the outer border 
of plaque, the green arrows highlight an area of calcification within plaque and *highlights the lumen in each 
sequence. (A) A 2D time of flight with the yellow arrow pointing towards the bifurcation. (B) A black blood 
sagittal oblique section through the bifurcation. (C) A corresponding cross sectional black blood imaging 
sequence through the common carotid artery bifurcation where plaque can be seen at the posterior aspect of the 
vessel wall. (D) A corresponding bright blood image at the same level. (E) A DCE parameter map of the cross 
sectional image. Ktrans is estimated using a Patlak model and a Ktrans map is generated. The Ktrans signal is 
shown in green. The boundaries of the plaque defined on the T1 weighted sequence are applied to this map to 
estimate the Ktrans measurement within the plaque. The white arrow highlights the Ktrans signal within the 
plaque area.
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of calcified plaque39, 40. In RA increased vascular calcification has been noted and found to be associated with CRP 
levels41. However to date, measurement of vascular calcification has been thought to reflect an overall increase in 
atherosclerosis burden in RA. Although the size of the control group is a major limitation in the current study, 
when compared with the literature, our data provides preliminary evidence to support early plaque calcification 
in RA and may suggest an altered natural history of plaque formation and progression. This highlights the need 
for further investigation into the role of chronic inflammation on vascular calcification in RA.
We found no difference in DCE measurements of plaque inflammation and neovascularisation between 
groups. There are a number of factors that may contribute to the negative finding. The first is the small sample 
size. At the time of study set-up, carotid DCE-MRI was a novel technique and little was known about the sample 
size required to power a study comparing DCE parameters. However, a study published in 2014 suggested that 50 
MRI datasets per group were required to achieve statistical power42. The increased prevalence of calcification in 
the RA group may also have confounded measurements of Ktrans. Calcium nodules are avascular, hence no con-
trast would enter this area of plaque which in turn could lead to a lower measured Ktrans in plaques with calcium. 
We noted a trend towards an inverse correlation between calcium content and Ktrans measurement, which accords 
with previous studies27, 43. Thus, higher calcium content of plaque is likely to have contributed to lower overall 
Ktrans values in the RA cohort in this study. Development of methods to exclude areas of calcification from the 
region of interest on DCE-MRI would go some way to address this issue and may be an area for further research.
A number of MRI scans (16/36) were not suitable for analysis mainly because the plaque thickness was <2 mm 
on MRI, despite reaching this threshold on US. US is operator-dependent even with expert sonographers. We also 
noted that in some cases, what appeared as plaque on US, was actually an area of minimal thickening at the origin 
of a small collateral branch off the carotid bulb on MRI. This may have led to an overestimation of plaque thick-
ness on US, a phenomenon not well described in the literature. No false positive or negative rates are available for 
US and MRI. However, in a study where MRI scans were performed in patients with plaque causing >15% steno-
sis on US, only 31/123 cases had plaque >2 mm thick44. Imaging small plaques can be technically challenging and 
evidence suggests the inclusion of plaques causing more than 30% stenosis or measuring plaque thickness on MRI 
at inclusion, may be a more reliable way of identifying plaque suitable for DCE-MRI analysis in future studies42, 45. 
While DCE-MRI appears to be an effective method of evaluating plaque inflammation in stroke patients, the 
large numbers that would need to be screened in order to obtain a sample size of 50 subjects with asymptomatic 
plaques may be a limiting factor when considering implementation of carotid DCE-MRI in larger RA studies 
in the future. However, only 14 subjects per group are required to power a study for compositional analysis of 
plaque, thus MRI is still a valuable and feasible option for the study of other high risk features of plaque in future 
studies34. We note the technical challenges of carotid MRI and that in any future study using these methods in an 
RA population, these feasibility factors should be considered.
PET findings. PET-MRI analysis was performed in 13 patients and a degree of FDG uptake was detected in 
all cases. Although normal values for FDG uptake within the carotid artery are not well established, a recent paper 
by Van Der Valk et al. proposed a threshold of SUVmax > 1.85 for significant carotid artery inflammation34. This 
Characteristics Patient Control P value
Plaque characteristics
  Plaque volume (mm3) 351.64 (217.14, 453.12) 309.93 (149.93, 706.12) 0.813
  Ktrans plaque (min−1) 0.0448 (0.030, 0.785) 0.0822 (0.569, 0.104) 0.194
  vp plaque (0–1) 0.070 (0.050, 0.097) 0.0478 (0.043, 0.274) 0.484
  Remodelling index 0.510 (0.480,0.60) 0.60 (0.485, 0.645) 0.483
  Calcium present* 11 (73.33) 1 (20.00) 0.038
  LRNC present* 13 (86.67) 4 (80.00) 0.560
  LRNC volume (mm3) 29.12 (15.20, 49.16) 61.26 (25.28, 95.38) 0.358
Traditional risk factors
  Age (years) 59.6 (56.2, 64.9) 59.0 (52.5, 65.5) 0.57
  Current smoker 2 (13.3) 0 —
  LDL (mmol/L) 2.96 (2.13, 2.28) 3.87 (3.28, 4.33) 0.081
  HDL (mmol/L) 1.55 (1.17, 2.01) 1.33 (1.25, 1.72) 0.860
  TC:HDL 3.33 (2.48, 4.04) 4.36 (3.77, 4.87) 0.176
  Systolic BP (mmHg) 147 (129, 161) 127 (117, 140) 0.079
  Diastolic BP (mmHg) 87 (79, 89) 78 (71, 89) 0.342
  History of 
hypertension 1 (6.67) 0
  History of diabetes 0 0
  History of clinical 
CVD 1 (6.67) 0
Table 3. Differences in plaque characteristics on MRI and traditional risk factors between the groups. Median 
(IQR) or frequency (%) where*. Ktrans: transfer constant, vp: partial volume of plasma, LRNC: lipid rich necrotic 
core, LDL low density lipoprotein, HDL: high density lipoprotein, BP: blood pressure.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 827  | DOI:10.1038/s41598-017-00989-w
value was proposed as it was above the 90th percentile in healthy volunteers who had no clinical cardiovascular 
disease, nor any significant risk factors. Other studies in Takayasu's arteritis have also suggested that an SUV max 
>1.3 signifies vascular inflammation46. If we apply the more conservative thresholds to our data 12/13 patients 
would be deemed to have significant inflammation. However we acknowledge that there were differences in 
acquisition and reconstruction methods between Van der Valk’s study and our own, so these may not be com-
pletely comparable data. Although no control group was included in the current study, in the published literature 
the prevalence of plaque inflammation in asymptomatic subjects is estimated to be 29% thus the current data 
would support the hypothesis that patients with RA may have more inflammatory plaques47.
Maki-Petaja et al. also demonstrated that patients with active RA had aortic inflammation on FDG-PET 
and that vascular inflammation improved following anti-TNF therapy8. Our data showing FDG uptake in 
non-atheromatous walls in RA patients, supports the hypothesis that RA patients have generalised arterial 
inflammation. However, in 5 cases we found a >30% higher SUVmax in plaque than in non-atheromatous wall, 
suggesting that plaque inflammation, is not simply a reflection of generalised wall inflammation, but a biomarker 
of an active inflammatory process that may result in plaque vulnerability and an enhanced risk of a future CVE. 
The significant correlation between CRP and FDG uptake supports the hypothesis that systemic inflammation 
not only influences plaque development but also plaque stability. Other studies have also reported an association 
between CRP and atherosclerosis, as well as future cardiovascular events in RA (48, 49). Our study adds to this 
literature by demonstrating a link between systemic and local plaque inflammation in RA and may explain why 
atherosclerotic lesions in RA are more vulnerable to early rupture.
PET-CT was well tolerated by patients and co-registration was possible with MRI sequences in all cases, sug-
gesting PET may be an effective method of quantifying plaque inflammation in future RA studies.
Limitations. We acknowledge several limitations to the study, including the limited power to detect differ-
ences in MRI measurements. We do note however that it provides valuable feasibility data with which to power 
future studies in this population. Additionally, subjects on statins were excluded from the study, as these agents 
influence MRI and PET measurements. This likely led to exclusion of patients at particularly high risk of CVD 
which whilst limiting generalisability would, if anything, bias us towards observing fewer differences between 
patients and controls.
Although the groups were age- and sex-matched, there was a higher prevalence of some traditional risk fac-
tors in the patient group, which meant that traditional risk factors may have contributed to the differences in 
plaque prevalence and phenotype observed on MRI. However the association between a number of measures of 
Figure 4. Provides an example of a carotid FDG-PET-MRI in an RA patient. (A) A cross sectional image at 
the level of the plaque. (B) Provides a more magnified image of the plaque on this slice which demonstrates 
increased uptake around the vessel wall where plaque has been identified (highlighted by the red arrow). (C) 
A coronal section in the same patient with the red arrow highlighting the area of increased uptake within the 
plaque in this view.
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inflammation including joint disease activity and IL6 levels remained significant on adjustment for traditional 
risk factors. This emphasises the importance of disease specific factors in the development of atherosclerosis in 
RA. Additionally the independent association between IL6 and plaque in patients strongly suggests that inflam-
mation is playing an important role in cardiovascular risk in RA.
We did not recruit a control group for the PET sub-study as the radiation exposure could not be justified in 
the context of a pilot study. PET and MRI were performed on different scanners and images were co-registered. 
While images were co-registered satisfactorily in all cases, small anatomical discrepancies due to differences in 
neck flexion could not be completely excluded and therefore, potentially may have contributed to a measurement 
error of SUVmax. This has been an inherent problem in the past, with PET-MRI studies being performed on sepa-
rate scanners, and not restricted to the current study.
In conclusion, we have shown an increased prevalence of atherosclerosis which was associated with classical 
cardiovascular risk factors and inflammation. On MRI we noted plaque calcification in RA patients, providing 
preliminary evidence to support earlier calcification and a more high risk plaque phenotype in this patient group. 
MRI and FDG-PET are well tolerated, feasible techniques to investigate plaque morphology and inflammation. 
However careful power and sample calculations are needed due to the technical demands involved. MRI and PET 
may provide the opportunity to interrogate the natural history of plaque and elucidate the influence of disease 
activity and anti-inflammatory therapies on atherosclerosis in RA. Additionally the development of combined 
PET-MRI scanners may allow a comprehensive assessment of morphology and inflammation of plaque in one 
imaging session which may be more feasible in patients with inflammatory joint diseases.
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